Literature DB >> 25717260

Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure.

Jan-Hendrik Bockmann1, Maura Dandri1, Stefan Lüth1, Nadine Pannicke1, Ansgar W Lohse1.   

Abstract

Acute hepatic failure due to hepatitis B virus (HBV) can occur both during primary infection as well as after reactivation of chronic infection. Guidelines recommend considering antiviral therapy in both situations, although evidence supporting this recommendation is weak. Since HBV is not directly cytopathic, the mechanism leading to fulminant hepatitis B is thought to be primarily immune-mediated. Therefore, immunosuppression combined with antiviral therapy might be a preferred therapeutic intervention in acute liver failure in hepatitis B. Here we report our favourable experience in three hepatitis B patients with fulminant hepatic failure who were treated by combining high-dose steroid therapy with standard antiviral treatment, which resulted in a rapid improvement of clinical and liver parameters.

Entities:  

Keywords:  Acute liver failure; Hepatitis B virus; Prednisolone; Reactivation; Rituximab

Mesh:

Substances:

Year:  2015        PMID: 25717260      PMCID: PMC4326162          DOI: 10.3748/wjg.v21.i7.2214

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  Viral clearance without destruction of infected cells during acute HBV infection.

Authors:  L G Guidotti; R Rochford; J Chung; M Shapiro; R Purcell; F V Chisari
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2012-03-20       Impact factor: 25.083

Review 3.  Hepatitis B virus infection: epidemiology and vaccination.

Authors:  Colin W Shepard; Edgar P Simard; Lyn Finelli; Anthony E Fiore; Beth P Bell
Journal:  Epidemiol Rev       Date:  2006-06-05       Impact factor: 6.222

4.  Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B.

Authors:  Keiichi Fujiwara; Shin Yasui; Yutaka Yonemitsu; Kenichi Fukai; Makoto Arai; Fumio Imazeki; Akihiro Suzuki; Hiroshi Suzuki; Tomohito Sadahiro; Shigeto Oda; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

Review 5.  Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.

Authors:  Gadi Lalazar; Deborah Rund; Daniel Shouval
Journal:  Br J Haematol       Date:  2007-03       Impact factor: 6.998

6.  Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.

Authors:  Sung-Nan Pei; Chien-Hung Chen; Chuan-Mo Lee; Ming-Chung Wang; Ming-Chun Ma; Tsung-Hui Hu; Ching-Yuan Kuo
Journal:  Ann Hematol       Date:  2009-08-21       Impact factor: 3.673

Review 7.  Control of cccDNA function in hepatitis B virus infection.

Authors:  Massimo Levrero; Teresa Pollicino; Jorg Petersen; Laura Belloni; Giovanni Raimondo; Maura Dandri
Journal:  J Hepatol       Date:  2009-06-10       Impact factor: 25.083

8.  The natural history of chronic hepatitis B virus infection.

Authors:  Brian J McMahon
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

9.  [Acute hepatitis B: is antiviral therapy indicated? Two case reports].

Authors:  J Girke; H Wedemeyer; J Wiegand; M P Manns; H L Tillmann
Journal:  Dtsch Med Wochenschr       Date:  2008-05       Impact factor: 0.628

10.  Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae.

Authors:  Christoph Jochum; Robert K Gieseler; Isabella Gawlista; A Fiedler; Paul Manka; Fuat H Saner; Michael Roggendorf; Guido Gerken; Ali Canbay
Journal:  Digestion       Date:  2009-10-15       Impact factor: 3.216

View more
  5 in total

1.  Corticosteroid and nucleoside analogue for hepatitis B virus-related acute liver failure.

Authors:  Keiichi Fujiwara; Shin Yasui; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

2.  Galectin‑9 ameliorates fulminant liver injury.

Authors:  Tomoko Tadokoro; Asahiro Morishita; Teppei Sakamoto; Shintaro Fujihara; Koji Fujita; Shima Mimura; Kyoko Oura; Takako Nomura; Joji Tani; Hirohito Yoneyama; Hisakazu Iwama; Takashi Himoto; Toshiro Niki; Mitsuomi Hirashima; Tsutomu Masaki
Journal:  Mol Med Rep       Date:  2017-05-18       Impact factor: 2.952

Review 3.  Glucocorticoid Treatment Strategies in Liver Failure.

Authors:  Chao Ye; Wenyuan Li; Lei Li; Kaiguang Zhang
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

Review 4.  Research Progress on the Pharmacological Action of Schisantherin A.

Authors:  Zehao Xiao; Wen Xiao; Guilin Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-12       Impact factor: 2.629

5.  A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 trans-Signaling and Cellular Infection with SARS-CoV-2.

Authors:  Julia Ettich; Julia Werner; Hendrik T Weitz; Eva Mueller; Roland Schwarzer; Philipp A Lang; Jürgen Scheller; Jens M Moll
Journal:  J Virol       Date:  2021-12-22       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.